Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21153188 | 0.85 | TBXAS1 (0.33) | CYP1A2CYP3A4GABRA1GABRB2CYP11B1 | |
| SCHEMBL23137839 | 0.83 | CYP1A2 (0.31) | CYP1A2CYP3A4GABRA1GABRB2CYP11B1 | |
| SCHEMBL14286957 | 0.82 | — | — | |
| SCHEMBL14465621 | 0.82 | HRH4 (0.35) | CYP1A2CYP3A4GABRA1GABRB2CYP11B1 | |
| SCHEMBL860093 | 0.81 | CYP11B2 (0.36) | CYP1A2CYP3A4GABRA1GABRB2CYP11B1 | |
| SCHEMBL27784191 | 0.81 | L3MBTL1 (0.32) | — | |
| SCHEMBL25159812 | 0.81 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL27111074 | 0.81 | HRH4 (0.37) | ALDH1A1TDP1HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL5658914 | 0.79 | ALDH1A1 (0.30) | ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL27141709 | 0.79 | HRH4 (0.36) | LMNAALDH1A1TDP1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2022-05-31 | — | — | US | disclosed |
| WO-2022099011-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2021-01-14 | — | — | US | disclosed |
| WO-2020247546-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | MERCK PATENT GMBH (DE) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345716-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | CYP1A2 2618/4885CYP3A4 867/4885GABRA1 1336/4885 |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | CYP1A2 110/4885CYP3A4 133/4885GABRA1 269/4885 |
| US-20170355703-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE | IDO1, IDO2, INMT | CYP1A2 186/4885CYP3A4 853/4885GABRA1 1826/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | CYP1A2 110/4885CYP3A4 133/4885GABRA1 269/4885 |
| US-20210009607-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | CYP1A2 2618/4885CYP3A4 867/4885GABRA1 1336/4885 |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | CYP1A2 350/4885CYP3A4 140/4885GABRA1 1153/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CYP1A2 4727/4885CYP3A4 4739/4885GABRA1 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.